Stevens Raymond C 4

What Happened

• Raymond C. Stevens, CEO of Structure Therapeutics (GPCR), received two grants on March 19, 2026: 260,217 restricted stock units (RSUs) and 322,230 derivative securities, each reported as acquired at $0.00. Combined, the awards total 582,447 share-equivalents. These were grants/awards (not open-market purchases or sales).

Key Details

• Transaction date: 2026-03-19. Form 4 filed: 2026-03-23 (no late‑filing flag shown in the excerpt).
• Grants and amounts: 260,217 RSUs (reported as award A) and 322,230 derivative securities (reported as award A); reported price per share: $0.00.
• Vesting/terms (from filing footnotes): F2 — RSUs represent contingent rights to receive one Ordinary Share each and “vest 1/4th annually on each anniversary of March 1, 2026,” subject to continued service. F4/F5 — the derivative award references an option-style structure where the exercise price equals fair market value on the grant date and vesting is 1/4 on March 1, 2027 with the remainder vesting in 36 equal monthly installments (subject to service).
• ADS note (F1): Ordinary shares may be represented by American Depositary Shares (ADSs); each ADS = 3 Ordinary Shares.
• Reporting/ownership: The grants are reported by Raymond Stevens (with F3 noting a co‑trustee relationship to a family trust). Shares owned after the transaction are not disclosed in the excerpt provided.

Context

• RSUs are contingent awards that convert to actual shares only as they vest; they are compensation/retention instruments rather than purchases that signal immediate personal investment. The derivative award appears to have option-like terms (exercise price tied to fair market value and multi-year vesting). These grants were awarded at no cash cost to the insider and do not indicate an immediate sale or market action.